Critical SAP FS-QUO and NetWeaver Vulnerabilities Exposed in March 2026 Security Patch Day: Immediate Action Required Rescana
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
